Lyell Immunopharma (LYEL)

• Market cap: $309M
• 1 day: -1.17%
• 5 days: -5.46%
• 1 month: -2.85%
• 3 months: -43.64%
• 6 months: -49.28%
• Year to date: -56.42%
• 1 year: 21.33%
• 5 years: -95.66%
• 10 years: -96.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Employees: 161